Palisade Bio Inc(PALI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 7:20 PM ET (Korea 10/30 08:20)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.54 | Insider Own | 7.77% | Shs Outstand | 173.6M | Perf Week | -11.85% |
| Market Cap | 0.21B | Forward P/E | - | EPS next Y | -25.89% | Insider Trans | -0.39% | Shs Float | 160.7M | Perf Month | -11.85% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | -0.06 | Inst Own | 96.77% | Short Float | 19.75% | Perf Quarter | -37.2% |
| Income | -0.03B | P/S | 414.76 | EPS this Y | 25.33% | Inst Trans | 7.91% | Short Ratio | 11.85 | Perf Half Y | -40.5% |
| Sales | 0.00B | P/B | 1.7 | EPS next 5Y | -3.67% | ROA | -47.68% | Short Interest | 31.75M | Perf YTD | -49.36% |
| Book/sh | 0.7 | P/C | 1.66 | EPS past 3/5Y | 89.33% 88.75% | ROE | -51.37% | 52W High | -58.32% ($2.86) | Perf Year | -43.87% |
| Cash/sh | 0.72 | P/FCF | - | Sales past 3/5Y | - | ROIC | -26.24% | 52W Low | 8.18% ($1.10) | Perf 3Y | -85.34% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 91.31% | Gross Margin | -0.4% | Volatility(W/M) | 8.26% 7.54% | Perf 5Y | -99.94% |
| Dividend TTM | - | EV/Sales | 164.42 | Sales Y/Y TTM | - | Oper. Margin | -7069.8% | ATR (14) | 0.11 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 24.25 | EPS Q/Q | 91.38% | Profit Margin | -6388.2% | RSI (14) | 31.58 | Recom | 1.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 24.25 | Sales Q/Q | - | SMA20 | -15.02% ($1.4) | Beta | 1.62 | Target Price | $10 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/10 | SMA50 | -28.84% ($1.67) | Rel Volume | 1.31 | Prev Close | $1.19 |
| Employees | 14 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 4.21% - | SMA200 | -35.84% ($1.85) | Avg Volume(3M) | 2.68M | Price | $1.19 |
| IPO | 2006/12/20 | Option/Short | No/Yes | Trades | 6716 | Volume | 3,499,369 | Change | - |
A U.S. clinical-stage biotech company developing therapeutics for gastrointestinal and inflammatory bowel diseases. Rather than generating direct revenue, this small-cap drug developer experiences significant share price volatility driven by pipeline clinical progress and funding activities, with clinical results for its lead candidate serving as the primary determinant of corporate value.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded more than usual. That is 131% of its average volume.
PALI has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +25.3% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $41,476. Peers typically go for $1,089.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 96.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #297 of 594 in the industry
Based on market cap of $207M.
FAQ
What kind of company is PALI?
PALI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PALI?
The market cap of PALI is approximately $207M, ranking 3,986 within its sector.
What is the 52-week high and low for PALI?
PALI has recorded a 52-week high of $2.86 and a low of $1.10.
